Regenera Pharma

Regenerative Therapy for Neuropathies

Health Tech & Life Sciences
Non Active, Nov 2020 ceased to operate
Series B Ness Ziona, Israel Founded 2008
LinkedIn
Last updated 2026-06-18
Total raised
$24.0M
Last: 2018-01
Stage
Series B
Founded
2008
Headcount
1
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences

About

Regenera Pharma is a clinical-stage pharmaceutical company developing innovative drugs for the treatment of optic nerve neuropathies. The company is currently focused on a treatment for ischemic optic neuropathy. Regenera will conduct a phase 3 study in the U.S. for evaluating the efficacy and safety of RPh201 treatment in participants diagnosed with NAION. It will also commence a phase 2 study in Canada that will evaluate the safety, tolerability, and clinical benefit of RPh201 in individuals with Alzheimers disease, with or without coexisting cerebrovascular disease. Regenera collaborates with the Henry Ford Health System to investigate the therapeutic effects of RPh201 on stroke recovery in a rat model of embolic middle cerebral artery occlusion (MCAO).

Funding history · 4 rounds · $24.0M total

2018-01
$20.0M
2015-05
$3.0M
2012-01
$400K
2011-01
$625K

Q&A

What is the current status of Regenera Pharma?
Regenera Pharma is currently inactive, having ceased operations in November 2020.
What was Regenera Pharma's primary focus?
Regenera Pharma was a clinical-stage pharmaceutical company focused on developing innovative drugs for the treatment of optic nerve neuropathies, specifically ischemic optic neuropathy.
What was the total amount of funding raised by Regenera Pharma?
Regenera Pharma raised a total of $24,025,000 across multiple funding rounds.
When was Regenera Pharma founded?
Regenera Pharma was founded in June 2008.
What was the most recent funding round for Regenera Pharma?
The most recent funding round for Regenera Pharma occurred in January 2018, with aMoon Fund participating.
What was Regenera Pharma's employee count?
Regenera Pharma had 1-10 employees.
What clinical studies was Regenera Pharma planning or conducting?
Regenera Pharma was planning a Phase 3 study in the U.S. for RPh201 in NAION patients and a Phase 2 study in Canada for RPh201 in individuals with Alzheimer's disease.
With which institution did Regenera Pharma collaborate on stroke recovery research?
Regenera Pharma collaborated with the Henry Ford Health System to investigate RPh201's effects on stroke recovery in a rat model.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 PatentsVerified

Tags

biopharmaceuticalneurologytissue-regenerationregenerative-medicinebiotechnologydegenerative-diseasesalzheimers-diseasecns-disorderspharmaceuticalspharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

LinkedInlinkedin.com/company/28148822

Identifiers & details

Founded2008-6
Employees (exact)1
Status reasonNon Active, Nov 2020 ceased to operate